




IMAGINEERING TECHNOLOGIES

Groundbreaking Approach to Cancer
Treatment for a Better Tomorrow



Groundbreaking Approach to Cancer Treatment for a Better Tomorrow

IMAGINEERING TECHNOLOGIES: FAST FACTS

Most brain cancers prove to be incurable by conventional means once the tumor grows to a certain size. That means old-school treatments like surgery and chemo fail to heal the patient. Imagineering Technologies is striving to overcome this horrible disease. In a world where patients struggle to cost-effective treatments -- or treatments that work at any price, for that matter -- we believe we can do better. Our proposed approach is a cost-effective means of treating these cancers.



KEY HIGHLIGHTS

- There is no cost-effective treatment of brain cancer beyond a critical size
- Imagineering Technologies Inc is proposing a unique integrated solution to this problem
- Large and expensive government-funded Carbon Ion Beam irradiation facilities exist in Japan and Europe for R&D purposes -- and some patient treatment
- Imagineering Technologies is targeting a \$50,000 per Glioblastoma patient full treatment cost



TARGET CUSTOMER

Hospitals, Cancer Treatment Centers, Cancer Patients



INDUSTRY

Pharmaceuticals and Biopharmaceuticals



MARKET SIZE

\$10 Billion+ USD per year





Groundbreaking Approach to Cancer Treatment for a Better Tomorrow

DEVASTATING PROBLEM

Conventional surgeries and chemotherapy have failed to cure most brain cancers, particularly when the tumor exceeds a certain size.

This life-threatening disease is nothing short of devastating.

We believe it's time to change that.

We believe it's time for a new treatment that will help patients overcome this horrible disease without breaking the bank.

Groundbreaking Approach to Cancer Treatment for a Better Tomorrow

GROUNDBREAKING SOLUTION

Imagineering Technologies will solve these problems by approaching cancer in a new way. Our proposed approach will lead to a cost-effective means of treating these cancers.

Many scientists are proposing genetic cancer treatment approaches, and our technical position is that a certain percentage of all cancer treatment will require radiation.

Our initial subject and target cancers are Glioblastomas, which consist of 52% all primary brain tumors. These patients have a very low survival rate with conventional treatment modalities.

We want to change that.



Groundbreaking Approach to Cancer Treatment for a Better Tomorrow

HOW WE'LL SUCCEED

Dr. Henry Makowitz intends to develop, and market:



Technology



Pharmaceuticals



And Tools



Specifically for cancer treatment

This includes:

Pharmaceuticals for the
control of Radiation
Susceptibility and Resistance

Heavy Ion Beam
Delivery Technology

Development of
Specialized Computers for
DNA/RNA repair modeling

Scanners for Very High
Resolution and High-Speed
Cancer Detection

More powerful
Antibiotics

Further, we propose to develop pharmaceuticals for the control of Radiation Susceptibility and Resistance from existing Biochemical and Biophysical processes in micro-organisms that exist in nature (some in extreme environments).

New antibiotics may also result from these enzymes and micro-organisms. These antibiotics will be investigated in a complementary effort to the development of pharmaceuticals for the control of Radiation Susceptibility and Resistance. This work will be a spin-off pharmaceutical effort, with minimum additional resources required from Imagineering and minimal additional technological and financial risk.





We are also dedicated to the development of Heavy Ion Beam Delivery Technology (primarily Carbon Ions), and the development of Specialized Computers for DNA/RNA repair modeling, which will utilize advanced Super-conducting Components and High-Strength Materials.

Fifty Angstrom Lithographic Processes will be developed for Super-Conducting Circuits. Quantum Computation will be explored. Low Temperature High Tc Magnet Technology will be developed for a Heavy Ion Beam Delivery System. The Scanners for Very High Resolution and High-Speed Cancer Detection will utilize proprietary Imagiengineering Technology.

Groundbreaking Approach to Cancer Treatment for a Better Tomorrow

WHAT WE KNOW AND HOW WE'LL BENEFIT

It is known that certain organisms exist in nature that are **very resistant to very high radiation fields and other extreme conditions**. Such organisms can be found coexisting naturally with very harsh natural physical environments. Their resistance and survival ability is due to their genetic capabilities to **rapidly repair their DNA and RNA**, as well as other cell functions from the damage caused by their environment.

If their genetic capabilities could be transferred to an unrelated organism by laboratory manipulation, it could change everything! However the theoretical details of these mechanisms are not known at this time. That said, the theory of evolution indicates that the biochemical processes found in all living organisms are not that dissimilar, and that processes found in one set of organisms will most likely map to another.



Imagineering Technologies hopes to isolate a number of organisms in their natural or man-made environments, and then (through biochemical studies) isolate the enzymes and DNA/RNA mechanisms responsible for resilience to extreme conditions and environments.



It is hoped that new pharmaceuticals will be developed from these enzymes, and DNA/RNA mechanisms, for the control of Radiation Susceptibility and Resistance. New antibiotics may also result from these enzymes and micro-organisms.

Note: The above arguments are based on the best scientific information available to date and general theoretical arguments. **Genetic transfer of certain genetic traits associated with radiation Resistance and Susceptibility has been demonstrated for one organism in the laboratory**, but genetic transfer across organism types is presently in question, although some debatable **evidence exists**.

BACKED BY RESEARCH

Imagineering Technologies isn't going at this blindly. While our innovation is fresh, our potential has already been proven.

In the peer-reviewed *Reviews of Modern Physics* ("Heavy-ion tumor therapy: Physical and radiobiological benefits," Volume 82, January-March 2010), results show that "high-energy beams of charged nuclear particles (protons and heavier ions) offer significant advantages for the treatment of deep-seated local tumors in comparison to conventional megavolt photon therapy."

Heavy-ion tumor therapy: Physical and radiobiological benefits

Dieter Schardt and Thilo Elsässer

GSI Helmholtzzentrum für Schwerionenforschung mbH (GSI), D-64291 Darmstadt, Germany

Daniela Schulz-Ertner

Markus-Krankenhaus, MVZ Radiologisches Institut, D-60431 Frankfurt/M., Germany

(Published 19 February 2010)

High-energy beams of charged nuclear particles (protons and heavier ions) offer significant advantages for the treatment of deep-seated local tumors in comparison to conventional megavolt photon therapy. Their physical depth-dose distribution in tissue is characterized by a small entrance dose and a distinct maximum (Bragg peak) near the end of range with a sharp fall-off at the distal edge. Taking full advantage of the well-defined range and the small lateral beam spread, modern scanning beam systems allow delivery of the dose with millimeter precision. In addition, projectiles heavier than protons such as carbon ions exhibit an enhanced biological effectiveness in the Bragg peak region caused by the dense ionization of individual particle tracks resulting in reduced cellular repair. This makes them particularly attractive for the treatment of radio-resistant tumors localized near organs at risk. While tumor therapy with protons is a well-established treatment modality with more than 60 000 patients treated worldwide, the application of heavy ions is so far restricted to a few facilities only. Nevertheless, results of clinical phase I-II trials provide evidence that carbon-ion radiotherapy might be beneficial in several tumor entities. This article reviews the progress in heavy-ion therapy, including physical and technical developments, radiobiological studies and models, as well as radiooncological studies. As a result of the promising clinical results obtained with carbon-ion beams in the past ten years at the Heavy Ion Medical Accelerator facility (Japan) and in a pilot project at GSI Darmstadt (Germany), the plans for new clinical centers for heavy-ion or combined proton and heavy-ion therapy have recently received a substantial boost.

DOI: [10.1103/RevModPhys.82.383](https://doi.org/10.1103/RevModPhys.82.383)

PACS number(s): 34.50.Gb, 87.50.–a, 87.53.Kn, 87.55.–x

CONTENTS

I. Introduction	383	3. Dependencies of RBE	405
II. Physical Aspects of Radiotherapy with Ion Beams	384	4. RBE determined from <i>in vivo</i> measurements	406
A. Energy deposition and dose	384	5. Dependence on oxygen status	407
1. Stopping of high-energy ions	385	B. Biophysical models in heavy-ion therapy	407
2. Energy-loss and range straggling	386	1. Biological optimization at LBL	408
3. Lateral beam spread	387	2. HIMAC approach	408
4. Nuclear fragmentation	388	3. Local effect model (GSI)	409
5. Neutron dose	389	a. Basic assumptions	409
B. Accelerators for ion-beam therapy	390	b. Integration into the treatment planning system	411
C. Beam delivery systems	391	c. Choice of parameters for clinical treatments	411
1. Passive beam shaping	391	4. Alternative approaches	411
2. Scanning systems	392	C. Implications for treatment planning	412
3. Gantries	394	D. Future directions	413
4. Irradiation of moving organs	395	IV. Clinical Experiences	414
D. Treatment planning and dose verification	397	A. Clinical trials investigating heavy-ion radiation therapy	414
1. Dose optimization	398	B. Future directions	416
2. Heavy-ion dosimetry	399	V. Conclusion	416
3. <i>In vivo</i> PET monitoring	399	Acknowledgments	417
E. Future directions	402	References	417
III. Biological Effects of Ion Irradiation	402		
A. Relative biological effectiveness	402		
1. Radiation damage by photons and heavy ions	403		
a. Microscopic track structure of ion beams	403		

I. INTRODUCTION

Radiotherapy plays an important role in the treatment

As if that weren't enough, many studies suggest that Heavy Ion tech could be effective in curing brain cancer. That research dates back to the 1950s! (refer to ; **Carbon ion radiotherapy in the treatment of gliomas: A review**, [Timothy D. Malouff](#), [Jennifer L. Peterson](#), [Anita Mahajan](#) & [Daniel M. Trifiletti](#) *Journal of Neuro-Oncology*, **Volume 145**, pages191–199 (2019)).

We are very excited about the potential to save lives. However, the current tech is extremely expensive. We can improve upon the effectiveness of treatment and, in the process, reduce the costs to a more manageable level. As a result, we will make it possible for more people to get the care they need.



MEET THE TEAM



Dr. Henry Makowitz

**FOUNDER, CEO, PRESIDENT AND
DIRECTOR | EXECUTIVE VP OF R&D**

- Has been employed by Cray Research, Inc., the Brookhaven National Laboratory, the Los Alamos National Laboratory, and the Idaho National Engineering Laboratory as a Physicist, Engineer and Computational Scientist
- Bachelor of Science in Physics from the State University of New York at Albany
- Masters of Science in Mechanical Engineering from the State University of New York at Stony Brook
- Ph.D. in Physics from the University of Texas at Austin



Mr. Mark Makowitz

DIRECTOR AND COMPANY SECRETARY

- Law Degree and B.A. in Accounting
- Operates his own Law Firm, Makowitz and Associates, in Denver, Colorado



Groundbreaking Approach to Cancer Treatment for a Better Tomorrow

MARKET OPPORTUNITY

The global market for effective pharmaceuticals (for the control of Radiation Susceptibility and Resistance in Cancerous and Adjoining tissues) is estimated to be **\$10 billion annually.**

New, more powerful antibiotics could have a **multi-billion-dollar annual market as well.**

And while genetic approaches to cancer treatment are projected to become the dominant technology of the future, Imagineering predicts that at least 25% of all cancer treatment will still involve some radiation procedures, and remain a market for its proposed pharmaceuticals.

Groundbreaking Approach to Cancer Treatment for a Better Tomorrow

BUSINESS MODEL & REVENUE STREAMS

We are pre-revenue but anticipate the following:

**MARKET
SIZE**

2 – 3

Glioblastomas

per 100,000
persons per year

**WORLD
POPULATION**

7.7

Billion persons

**TOTAL TREATMENT
PRICE ASSUMED PER
PATIENT**

\$50,000

(includes scans,
pharmaceuticals, and
carbon ion irradiation)

COMPETITIVE OVERVIEW

Competitor	Pharmaceutical and/or Biopharm Company	Hard/Software dev co (ex: IBM or Siemens)	Startups
KEY STRENGTHS	Immense size Access to plenty of capital	Immense size Access to plenty of capital	Can follow a focused R&D plan
KEY WEAKNESSES	Lack of focus on one type of product No integrated technology approach No hardware development experience	Lack of experience in development of pharmaceuticals and/or bio-pharmaceuticals	Lack of experience in related R&D that Dr. Henry Makowitz brings to Imagineering Technologies (more than 40 years of R&D experience)

Groundbreaking Approach to Cancer Treatment for a Better Tomorrow

INVESTMENT OPPORTUNITY

For this round, Imagineering Technologies is seeking a **total raise of \$4,000,000 in equity**.

The funds will allow us to develop three Hardware Prototypes and establish Scientific Feasibility for its Bio-Pharmaceuticals.

Our anticipated use of funds includes:

	min	max
Administration & Travel	\$250,000	\$400,000
R&D (Labs, Offices, etc.)	\$650,000	\$1,000,000
Capital Expenses	\$200,000	\$500,000
Salaries	\$600,000	\$1,800,000
TOTAL	\$1,700,000 to \$3,700,000	

Groundbreaking Approach to Cancer Treatment for a Better Tomorrow

WHY INVEST?

Imagineering Technologies wants to put an end to the suffering caused by terminal brain cancer.

With thousands of fatal cases estimated to occur every year in the United States alone (and many more globally), we are eager to provide patients with a more effective -- and cost-effective -- treatment.

Backed by research, we believe our groundbreaking solution is the breakthrough the world has been waiting for.

Now we need your help to to execute on our vision.



For more information on this investment opportunity, please contact:



Henry Makowitz

imagineering99@yahoo.com

208 524-2719